CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

DBV Technologies' Viaskin Peanut Patch Reduces Reaction Severity in Phase 3 Trial in Children

By Public Technologies
  • DBV Technologies presented new Phase 3 VITESSE results for its Viaskin Peanut Patch at the 2026 ACAAI meeting.
  • The trial met its primary endpoint in peanut-allergic children ages 4-7; treatment reduced allergic reaction severity versus placebo over 12 months.
  • Immune changes were consistent with allergen immunotherapy, supporting the patch's treatment effect.
  • High treatment compliance without restrictions on daily activities supported potential use in children's routines if approved.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121000OMX_____CNEWS_EN_GNW1001303334_en) on November 12, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk